Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update

NEXT STORY
Chi-Med Highlights Presentation of Clinical Data from the Successful SANET-ep Phase III Trial at ESMO Annual Meeting
PREV STORY
Sequana Medical Announces First Patient Enrolled in North American alfapump® Pivotal Study (POSEIDON)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn’s Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting

author_avatar
NASDAQ Market News

Editas Medicine Presents Pre-Clinical Data Supporting the use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies

author_avatar
NASDAQ Market News

Bavarian Nordic Completes Enrollment of First Stage in Chordoma Phase 2 Trial

COPENHAGEN, Denmark, January 25, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced ...

author_avatar
NASDAQ Market News